NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETIMOL (timolol) is a non-selective beta-adrenergic receptor antagonist ophthalmic solution approved in 1995 for reducing intraocular pressure in open-angle glaucoma, ocular hypertension, normal tension glaucoma, and ocular surface disease. Administered as eye drops, timolol works by decreasing aqueous humor production to lower IOP and reduce the risk of optic nerve damage.
$3.0MPart D
LOE ApproachingBETIMOL faces imminent loss of exclusivity with modest Part D spending ($3M) and declining market relevance; team focus likely shifting to lifecycle management and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Started Oct 2025
228 enrolled
Glaucoma
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Started Sep 2021
50 enrolled
Ocular Surface DiseasePrimary Open Angle Glaucoma
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Started Mar 2021
84 enrolled
Primary Open Angle GlaucomaOcular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Started Dec 2020
323 enrolled
Primary Open Angle GlaucomaOcular Hypertension
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
Started Dec 2018
70 enrolled
OAG - Open-Angle GlaucomaOHT - Ocular Hypertension
Worked on BETIMOL at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.